Woodline Partners LP Purchases 1,292,927 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• Woodline Partners LP has significantly increased its stake in COMPASS Pathways PLC, buying an additional 1,292,927 shares, bringing its total to 1,754,856 shares.
• Analysts have set various price targets for COMPASS Pathways, with a consensus target of $16.29 and multiple ratings including “buy” and “hold”.
• COMPASS Pathways currently trades at approximately $5.20 per share, and the company's market cap stands at $498.89 million.

Woodline Partners LP grew its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 279.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,754,856 shares of the company's stock after buying an additional 1,292,927 shares during the period. Woodline Partners LP owned approximately 1.89% of COMPASS Pathways worth $5,019,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Polar Asset Management Partners Inc. acquired a new stake in shares of COMPASS Pathways in the first quarter worth about $657,000. Jane Street Group LLC lifted its position in shares of COMPASS Pathways by 72.7% in the fourth quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock worth $196,000 after buying an additional 21,815 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after buying an additional 5,003 shares during the last quarter. Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter worth about $3,780,000. Finally, ARK Investment Management LLC lifted its position in shares of COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock worth $5,162,000 after buying an additional 68,601 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded up $0.04 during trading on Thursday, reaching $5.08. The company's stock had a trading volume of 1,059,474 shares, compared to its average volume of 1,802,597. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82. The business's fifty day moving average price is $4.46 and its 200-day moving average price is $3.92. The firm has a market cap of $486.90 million, a price-to-earnings ratio of -2.76 and a beta of 2.17. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $7.53.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). As a group, equities research analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CMPS shares. HC Wainwright reduced their price target on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Evercore ISI reiterated an "in-line" rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $12.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, May 27th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price objective on shares of COMPASS Pathways in a research note on Friday, August 1st. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, COMPASS Pathways has a consensus rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.